Structured benefit–risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5795 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Marie-Laure Kürzinger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, Global Epidemiology and Benefit-Risk, PSPV, Gentilly, France. Hauptthemen laut MEDLINE: Enoxaparin, Pulmonary Embolism, Venous Thrombosis, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Purpose
Guidelines recommend low‐molecular‐weight heparins (LMWHs) for patients with cancer‐associated thrombosis. However, until recently, only dalteparin and tinzaparin were approved in the European Economic Area (EEA) for these patients. This study compares the benefit–risk profile of enoxaparin with dalteparin and tinzaparin for the extended treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrence in adult patients with active cancer.
Methods
A semi‐quantitative structured benefit–risk assessment was conducted for the label‐extension application of enoxaparin based on the benefit–risk action team descriptive framework: define decision context; determine key benefit and risk outcomes; identify data sources; extract data; interpret results.
Results
The key benefits were defined as reduced all‐cause mortality and venous thromboembolism (VTE) recurrence (including symptomatic DVT, fatal PE or non‐fatal PE); the key risks were major and non‐major bleeding of clinical significance, and heparin‐induced thrombocytopenia (HIT). Enoxaparin demonstrated comparable effects for the reduction of VTE recurrence and all‐cause mortality versus other EEA‐approved LMWHs (dalteparin, tinzaparin). There was no evidence of a significant difference between enoxaparin and the comparator groups with regard to incidence of major and non‐major bleeding. The data on HIT were too limited to assess the difference between the two groups.
Conclusions
The assessment demonstrated a favourable benefit–risk profile for enoxaparin similar to that of other EEA‐approved LMWHs for the treatment of DVT and PE and the prevention of recurrence in patients with active cancer and thus supported the label‐extension approval.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sanofi, Global Epidemiology and Benefit-Risk, PSPV, Gentilly, France.
- Sanofi, Global Patient Safety & Pharmacovigilance, Gentilly, France.
- Sanofi, Global Regulatory Affairs-EU-GenMed, Vienna, Austria.
- Sanofi, Global Medical Evidence Generation, Basel, Switzerland.
- Sanofi, Global Medical Cardiovascular, Paris, France.
ORCID-Profile: Marie-Laure Kürzinger, Denis Granados
Förderung
- Sanofi
Zitieren
APA
Kürzinger, M. L., El-Haddad, C., Gouin-Soboleva, T., Fazekas, Z., Granados, D., Benito-Garcia, E., & Djoudi, Y. (2024). Structured benefit–risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5795
Vancouver
Kürzinger ML, El-Haddad C, Gouin-Soboleva T, Fazekas Z, Granados D, Benito-Garcia E, et al. Structured benefit–risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5795
BibTeX
@article{Krzinger2024,
author = {Kürzinger, Marie-Laure and El-Haddad, Chantal and Gouin-Soboleva, Tatiana and Fazekas, Zita and Granados, Denis and Benito-Garcia, Elizabeth and Djoudi, Yasmina},
title = {Structured benefit–risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5795}
}
EUVIMED